Triple-drug transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: Assessment of survival in 124 consecutive patients

American Journal of Roentgenology

Volumn 193, Issue 6, 2009, Pages 1665-1671

  Gomes, Antoinette S ^a   Rosove, Michael H ^a   Rosen, Peter J ^a,b   Amado, Rafael G ^a,c   Sayre, James W ^a   Monteleone, Phillip A ^a   Busuttil, Ronald W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Tower Cancer Research Foundation ^*  (United States)

^c AMGEN INC   (United States)

Author keywords

Hepatocellular carcinoma; Liver disease; Transcatheter arterial chemoembolization; Triple drug transcatheter arterial chemoembolization

Indexed keywords

BILIRUBIN; CISPLATIN; DOXORUBICIN; MICROCRYSTALLINE COLLAGEN; MITOMYCIN C;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACRYLIC RESINS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGRAPHY, DIGITAL SUBTRACTION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; COLLAGEN; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; GELATIN; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MITOMYCIN; PROPORTIONAL HAZARDS MODELS; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 73449083429     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.08.1806     Document Type: Article

References (27)

1. Annex table 2: deaths by cause, sex, mortality stratum in WHO regions, estimates for 2002. In: The World Heath report 2003. Geneva, Switzerland: World Heath Organization, 2003:156
2. Parkin DM, Whelan SL, Ferlay J, et al., eds. Cancer incidence in five continents, vol. VII. Lyon, France: International Agency for research on Cancer, 1997
3. Lin DY, Liaw YF, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Gastroenterology 1988; 94:453-456
4. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11:181-184 5. Madden MV, Krige JE, Bailey S, et al. Randomised trial of targeted chemotherapy with Lipio dol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993; 34: 1598-1600
5. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. A comparison of Lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332:1256-1261
6. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with Lipio dol chemoembolization: a multicenter randomized trial. J Hepatol 1998; 29:129-134
7. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224:47-54
8. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37:429-442
9. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171
10. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002; 359:1734-1739
11. Brown DB, Pilgram TK, Darcy MD, et al. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 2005; 16:1661-1666
12. Solomon B, Soulen MC, Baum RA, Haskal ZJ, Shlansky-Goldberg RD, Cope C. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol 1999; 10:793-798
13. Baron RL. Understanding and optimizing use of contrast material for CT of the liver. AJR 1994; 163:323-331
14. Noguchi Y, Murakami T, Kim T, et al. Detection of hepatocellular carcinoma: comparison of dynamic MR imaging with dynamic double arterial phase helical CT. AJR 2003; 180:455-460
15. Kaufman SL, Strandberg JD, Barth KH, White RI Jr. Transcatheter embolization with microfibrillar collagen in swine. Invest Radiol 1978; 13:200-204
16. Sniderman KW, Sos TA, Alonso DR. Transcatheter embolization with Gelfoam and Avitene: the effect of Sotradecol on the duration of arterial occlusion. Invest Radiol 1981; 16:501-507
17. Nakao N, Ohnishi M, Shimada T, et al. Transcatheter hepatic arterial embolization with Avitene in dogs. Cardiovasc Intervent Radiol 1991; 14:124-128
18. Nakabayashi K, Makoto N, Handa T, Keino H, Takahashi M, Sugita K. Evaluation of particulate embolic materials with MR imaging, scanning electron microscopy, and phase-contrast microscopy. AJNR 1997; 18:485-491
19. Daniels JR, Kerlan RK Jr, Dodds L, et al. Peripheral hepatic arterial embolization with crosslinked collagen fibers. Invest Radiol 1987; 22:126-131
20. Struk D, Rankin RN, Karlik SJ. Stability studies on chemoembolization mixtures: dialysis studies of doxorubicin and lipiodol with Avitene, Gelfoam and Angiostat. Invest Radiol 1993; 28:1024-1027
21. Reed RA, Teitelbaum GP, Daniels JR, Pentecost MJ, Katz MD. Prevalence of infection following hepatic chemoembolization with cross-linked collagen with administration of prophylactic antibiotics. J Vasc Interv Radiol 1994; 5:367-371
22. Diamond NG, Casarella WJ, Bachman DM, Wolff M. Microfibrillar collagen hemostat: a new transcatheter embolization agent. Radiology 1979; 133:775-779
23. Takayasu K, Arii S, Ikai I, et al.; Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131:461-469
24. Geschwind JF, Ramsey DE, van der Wal BC, et al. Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol 2003; 26:111-117
25. Gomes AS, Rosove MI, Amado R, Rosen P, Sayre JW, Monteleone PA. Transarterial hepatic chemoembolization in patients with hepatocellular carcinoma. (abstr) In: Radiological Society of North America scientific assembly and annual meeting program. Oak Brook, IL: Radiological Society of North America, 2004:219
26. Yuen MF, Chan AO, Wong BC, et al. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. Am J Gastroenterol 2003; 98:1181-1185
27. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31:339-346